Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative nivolumab plus chemotherapy versus placebo plus chemotherapy in resectable stage II-IIIB non-small cell lung cancer
NL-OMON55271Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Event-free survival. Started Jan 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55271.